Of most interest, Lisberg et al. reported the role of immunotherapy with Pembrolizumab as first-line for EGFR-mutant NSCLC patients with PD-L1 expression of at least 1%, confirming once again the failure of immunotherapy alone for EGFR mutant patients (12). The gene discussed is CD274; the disease is non-small cell lung carcinoma.